Ruxolitinib
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Explore 59 assets in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Jonathan Brammer
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07356245CT.gov Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | — | Recruiting | — | — | — |
NCT07283822CT.gov Amping up With PemJAK | — | Recruiting | — | — | — |
NCT03017820CT.gov A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ruxolitinib (this asset) | Jonathan Brammer | P2 | B · 58 |
| (+)-Vincristine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Cyclophosphamide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Dexasone | National Cancer Institute (NCI) | P2 | BBB |
| Bexarotene | Case Comprehensive Cancer Center | P4 | BBB |
| Adriamycin | Falo, Louis, MD | P4 | BBB |
| Nivestim | City of Hope Medical Center | P4 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BBB |
| Mogamulizumab | University of Michigan Rogel Cancer Center | P4 | BB |
+42 more in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort
Other indications for Ruxolitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Myelofibrosis | — | P4 | BBB · 73 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BB · 70 |
| Graft Versus Host Disease | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ruxolitinib in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ruxolitinib-primary-cutaneous-t-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →